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SUMMARY
In order to study the disposition of ENDOTELON in humans, this compound was labelled with 14C by photosynthesis.
ENDOTELON consists of a complex of procyanidolic oligomers extracted from the seeds of a variety of vine cultivated in the
Bordeaux wine-growing region, and is prescribed for the treatment of chronic venous insufficiency and retinal lesions.
Considering the difficulty in labelling the various constituents of the product, the labelling procedure was based on providing
radioactive CO2 to the plant. After isolation and purification, 150 mg of active material (50 ftCi) was administered orally to six
healthy volunteers. Radioactivity was measured in the blood over time until 72 and 120 hours in the same subjects after drug
administration. Urinary and faecal elimination was measured for a period of 167 hours. Urinary elimination of the radioactive
compounds represented 12 to 27% of the administered dose and faecal elimination represented 47 to 75% depending on the subject.
The radioactivity of the 14C02eliminated in the breath was also measured, and represented around 8% of the total radioactivity for
the 72-hour period after administration.
Although the disposition of ENDOTELON is based on the total radioactivity measured over time, this technique allows the
evaluation of the elimination rate of the product and its metabolites from the human body.
INTRODUCTION
ENDOTELON@ is a product that is prescribed for
the treatment of chronic venous insufficiency and
retinal lesions (1).
At cell level, ENDOTELON@ becomes fixed at
mucopolysaccharide level by interfering with the
biosynthesis of collagen fibres. This accounts for the
reinforcing and protective effect on the vascular coat
of the microcirculation of the venous system (2).
From a pharmacological point of view, the
therapeutic effect of ENDOTELON@ on capillary
fragility and on venous tonus results in:
an increase in capillary resistance, as demon-
strated by double-controlled studies including a
placebo and a reference substance,
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- a reduction in capillary permeability, as evidenced
by various tests (histamine, Landis tests, isotopic
method),
- an increase in venous tonus as determined by gas
plethysmography in cases of venous occlusion (3),
The active constituents of ENDOTELON consist
of a group of procyanidolic oligomers extracted
from the seeds of a variety (UNIBLANC) of vine
that is essentially cultivated in the Bordeaux (France)
wine-growing region (Figure 1).
In order to investigate the disposition of this com-
pound, this study was carried out using a 14C-Iabelled
compound, and adopting the appropriate techniques
for radioactive measurement (4,5).
In this study 14C-Iabelled ENDOTELON was
synthesized by photosynthesis and a pharmaceutical
form containing the labelled material was prepared
and administered to six healthy human volunteers.
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Figure I. HPLC separation of procyanidolic oligomers
In this paper the specifications of the labelled
compound as well as the procedure of the labelled
synthesis was described.
A plant of the UNIBLANC strain was enclosed in a
300 L airtight polyethylene chamber. A 14COZ
atmosphere was obtained in a generator from Ba
14C0 2(56.6 mCi/mM) and 60% H3P04• The duration
of the procedure was 8 days. The grapes were picked
about 6 weeks after the labelling procedure, refriger-
ated in liquid nitrogen and stored at -30°C until
processing. The procyanidolic oligomers, which
constitute the active principle of ENDOTELON, were
extracted from the seeds using a mixture of ace-
tone/water (20/80). After different steps in the
procedure (acetone elimination, NaCl saturation,
ethyl acetate extraction) the compound was obtained
by precipitation in chloroform.
. Different specific activity lots were obtained and,
m order to respect the therapeutic dose of the com-
pound and bearing in mind the level of J,.lCi that the
Medical Commission of the University Hospital has
authorized, ENDOTELON was prepared with a spe-
cific activity of 9.694 and 12.321 KBq/mg (6,7).
MATERIAL AND METHODS
Administered pharmaceutical form
ENDOTELON in the form of a slightly light
brown tinted powder was administered without
excipient, directly introduced into a capsule (No 0) at
a dose of 150 mg with a total activity of around 50
J,.lCi per capsule (l.85 MBq) to the first three volun-
teers, and with a total activity of around 40 J,.lCi
(1.48 MBq) to the other three
volunteers.
Experimental protocol
The experiment was conducted in six healthy volun-
~eers: four females and two males who had been fully
informed of the nature of the experiment and of the
study protocoL Preliminary authorization was ob-
tained from the Medical Ethics Committee of the
University Hospital where this study was carried out.
A detailed study project, namely regarding dosimetry,
was submitted to the Ethics Committee in this respect.
T~e data regarding the volunteers - age, body weight,
height and body mass - have been given in Table I.
Prior to entry into the study, haematological and
biochemical analyses and clinical examinations were
performed.
Before oral administration of the product, the sub-
jects fasted. Two hours after administration of the
drug, they received a light breakfast. Thereafter they
were able to eat normally. However, they had to
absta.in from ingesting beverages containing alcohol,
caffeine and other alkaloids.
Blood samples (5 ml blood on 0.5 ml of a 3.8 %
monosodic citrate solution) were drawn via a
permanent butterfly type catheter inserted into a
superficial forearm vein of each volunteer.
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Table I. Characteristics of volunteers
No Subject Year Sex Weight(kg) Height(cm) Bodysurface(ni)
I A:R.B. 64 Female 50 kg 168 cm 1.56m2
2 B :P.R. 27 Male 64 kg 174 em 1.77m2
3 C:C.W. 33 Female 48 kg 154cm 1.43m2
4 D:M.M. 34 Female 47 kg 163 em 1.48m2
5 E:J.M. 40 Male 65 kg 170cm 1.75 m2
6 F:M.S. 39 Female 53 kg 163cm 1.56m2
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The blood samples were collected at 30 minutes, 1
hour, 1.30, 2, 3, 4, 5, 6, 8, 10, 24, 48 and 72 hours and
for volunteers D, E and F at 120 and 144 hours after
drug administration.
Plasma was obtained by centrifugation (8,000 g) of the
blood.
Radioactivity at plasmatic level was measured in 0.5
rnl samples using an appropriate scintillation cocktail
containing a large volume of water. Absolute values for
radioactivity were obtained after correction using the
external standard method.
All urines eliminated by each volunteer during the
experimental period - over a 167 h period for volunteer
A and 70 h for the others were collected according to
the natural rhythm of elimination. Each miction was
collected separately. The volume of elimination was
recorded and the radioactivity measured by liquid
scintillation according to a previously described tech-
niques (5). After correction, the values of the urinary
elimination of the product and its metabolites were
expressed in % of the eliminated dose of urine over the
period in question.
The faeces were collected in an appropriate recepta-
cle for each defaecation according to the natural
rhythm of excretion over a period of 7 days after
administration of the drug.
The weights of fresh and desiccated faeces were
determined and the radioactivity was measured in dry
100 mg samples by a combustion technique (8). After
correction, the values of faecal elimination were ex-
pressed in % determined compared to the quantity of
drug administered.
Presumably the procedure used for labelling resulted in
the introduction of 14C in more than one chemical posi-
tion of the molecules in question and the metabolic
pathway of this compound produced radioactive CO2
that was eliminated in the breath.
Radioactivity measurement at pulmonary
level
The radioactivity of 14C0 2 eliminated in breath was
measured by liquid scintillation technique. CO2 was
quantitatively absorbed by a mixture of phenyletha-
nolamine hydroxide of hyamine in methanol over a
predetermined time period and at spaced out inter-
vals. The values were expressed as % of the elimi-
nated dose using a linear elimination rate.
RESULTS
Haematological and biochemical data
.Haematological and biochemical data for the six
subjects show that the values determined for all the
volunteers were within the normal physiological lim-
its.
Plasma levels
The levels of ENDOTELON and its labelled
metabolites as a function of time were determined by
the measurement of plasma radioactivity, and ex-
pressed in terms of nanogram equivalents of the ad-
ministered product and based on its specific activity.
The values were expressed as means and standard
deviation (means ± SD) and have been given in Figure
2.
From these results, interindividual differences at
calculated standard deviation level can be seen.
Nevertheless the drawn curve shows that the
maximum value was measured around 14 hours after
drug administration and that the decrease was
relatively low, as after 144 hours, at which time the
results for the last three subjects (i.e. D,E,F) were
recorded, the values were almost similar to those
measured at two and three hours.
Urinary elimination
The urinary elimination of 14C ENDOTELON and its
labelled metabolites were measured as a function of
time in six subjects.
The values of urinary elimination were expressed
as % of the administered dose for the first hour and
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for the periods of 0-24, 24-48, 48-72 hours for
subjects A, B and for the other subjects, i.e. C, D, E,
F for the period of 72-96 and 96-120 hours (not
appeared in Figure 3). For the subject A, the
elimination rate was measured up to 168 hours after
drug administration.
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Figure 2. Plasma levels as a function of time (average values and standard deviation in 6 subjects) after oral administration of a 150 mg
dose of 14C-ENDOTELON. Values on a semi-logarithmic scale are expressed in ng equivalent of unchanged product per ml of plasma
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Figure 3. Cumulated urinary elimination as a function of time of 14C-ENDOTELON and its labelled metabolites after oral
administration of a 150-mg dose to 6 healthy volunteers.Cumulated values are expressed as % of the administered dose
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Figure 4. Cumulated faecal elimination as a function of time of 14C-ENDOTELON and its labelled metabolites after oral
administration of a 150-mg dose to 6 healthy volunteers.Cumulated values are expressed as % of the administered dose
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Despite interindividual vanations, the elimination
were coherent compared with the mean values of the
elimination in each subject. The urinary elimination
rate was around 12 and 27 % of the administered dose.
The urinary elimination as a cumulated value and
as a function of time for each subject has been
shown in Figure 3.
Faecal elimination
The faecal elimination of 14C-ENDOTELON and its
labelled metabolites were measured as a function of
time in all six study subjects.
The values of the elimination rate were expressed
as % of the administered dose for the time intervals
during the first 24 hours and for the periods from
0-24, 24-48, 48-72, 72-96, 96-120 and 120-144
hours for three subjects, i.e . A, C. F and 144-168
hours (7 days) for three other subjects, i.e. B, D, E
after drug administration. These values have been
shown for each subject in Figure 4.
Although interindividual variations as regards
the % eliminated by this route were observed, we can
consider that the results represented average of fae-
cal elimination.
Pulmonary elimination
Considering the nature of the labelling by 14C which
is general for all carbons of the compound, it is
important to evaluate the degree of degradation of
the compound structure through the formation of
14C0 2>2 which is eliminated via the breath. This rate
was evaluated during two-hour periods - for the first
12 hours and for longer periods thereafter. The time
periods as well as the elimination rate were expressed
as % of the administered dose, whereas the cumula-
tive values for the period of 24 hours and up to 72
hours were recorded, and have been given in Table
II.
From these results it can be seen that the elimination
rates via this route were relatively similar for all six
subjects, and that the most important part was elimi-
nated during the first 24 hours after drug administra-
tion.
The breath elimination rate amounted to around 8%
of the administered dose. This value indicates the
metabolic degradation of the ENDOTELON-
labelled compounds.
Table II. 14C02elimination by pulmonary route in man for a period of 72 hours after oral administration of 14C ENDOTELON. Values
are expressed as % of he administered dose
Time after drug administration (h) Study subjects
A B C D E F M±20
0-24 4.67 8.58 5.45 en 9JJ7 5.41 15.62 ±5.55
2448 - - - - . - -
48-72 1.58 0.343 1.71 0.43 3.15 1.54 6.09±3.97
0JJ72 0.52 0.89 0.50 0.31 ±O.l9
Total 6.25 8.99 7l:J3 7.20 13.11 7.45 6.44±2.38
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Figure5. Comparison of urinary. faecal and pulmonary elimination of 14C END01FLON and its metabolites. Cumulated values over a
period of 96 hours are expressed as % eliminated as compared to the administered dose
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Table III. Balance sheet of urinary, faecal and pulmonary elimination over a 96-hours period of ENDOTELON and its metabolites in
man after oral administration of the drug. Values are expressed as % of he administered dose
Route of elimination % of the administered dose
A B C D E F M±2cr
Urinary 10.96 2131 26.31 25.20 27.27 21.48 22.09±5.99
Faecal 67.54 46.24 48.27 21.69 39.91 50.03 45.61 ± 14.92
Pulmonary 6.26 8.99 7.69 8.29 13.24 7.43 8.65 ± 2.43
Total 84.76 76.54 82.27 55.18 80A2 78.94 76.35 ±10.74
Comparison of urinary, faecal and
pulmonary elimination
The cumulated individual values expressed as % of
the administered dose over 96 hours have been given
in Table III.
The total elimination for the selected period of 96
hours was around 76% of the administered dose.
These results can be seen in Figure 4.
DISCUSSION
Considering the guidelines of the Medical Ethics
Committee of the University Institution for
experiments in man with radioactive tracer-labelled
compounds. it was necessary to establish as precise
as possible a balance between the amount of
administered labelled compound and its elimination.
Indeed. the Ethics Committee considers such a
balance to be an extremely important factor. as it is a
means of assessing the volunteers' exposure to
ionizing irradiation.
As expected, plasma levels were relatively low
considering the ISO-mg dose of ENDOTELON
administered.
As regards the chemical structures of the
administered products which constitute
ENDOTELON. it is likely that they underwent a
first-pass in the liver.
The values of urinary elimination varied from one
subject to another but considering the results of
faecal elimination, they can be compared, namely
for almost all subjects with the exception of subject
D whose faecal elimination was much lower than
that of the others.
Concerning the rate of urinary elimination, it was
observed that the greater part of the latter took place
within 72 hours after drug administration. The
quantities eliminated thereafter were very low. This
is the reason why urine collection was no longer
performed after 72 hours apart from subject A.
The faecal elimination was significant and
amounted to 47% of the administered dose,
essentially up to four days after drug administration.
The interindividual variations observed, namely for
the subject A, must be considered in relation to his
urinary elimination.
The quantities measured at faecal level must be
partly attributed to elimination of the drug by biliary
route, probably under the form of metabolites rather
than to transit resulting from poor absorption.
Regarding the radioactivity measured at breath
level, which must be attributed to the transformation
of the ENDOTELON-Iabelled compound, although
it was of significance, namely for determining the
elimination balance analysis, it remained rather low.
Taking into account this last elimination route, the
values of the balance sheet for the subject A were
high, i.e. about 76% over a 7-days period after
drug administration. Given this finding, it is possible
that elimination via this route would continue to take
place over the following days (Figure 4).
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